Evidence map›Paper›PMID 41634464›Full record

ArticleNature aging2026

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome.

Estela González-Gualda, Marika A V Reinius, David Macias, Samir Morsli, Jianfeng Ge, Ioana Olan, José Ezequiel Martín, Hui-Ling Ou, Muhamad Hartono, María Pilar Puerto-Camacho and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Platinum accumulation in chemotherapy: toxicity mechanisms, challenges, and mitigation strategies.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Estela González-Gualda *Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Marika A V Reinius *Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
David MaciasEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-8676-1964
Samir MorsliEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-0371-0732
Jianfeng GeEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Ioana OlanCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-0692-1831
José Ezequiel MartínCMDL, Department of Oncology, University of Cambridge, Cambridge, UK.
Hui-Ling OuEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Muhamad HartonoEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
María Pilar Puerto-CamachoEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Mary DenholmEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-5875-4487
Rosalind KieranEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Reuben HoffmannDepartment of Biomedical Engineering, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Mark DaneDepartment of Biomedical Engineering, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Dimitris VeroutisDepartment of Histology-Embryology, Medical School, National Kapodistrian University of Athens, Athens, Greece.
Guillermo MedranoMolecular Imaging Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Francisca MuleroMolecular Imaging Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0001-9584-4211
Mercedes Jimenez-LinanCambridge University Hospitals NHS Foundation Trust, Department of Pathology, Addenbrooke's Hospital, Cambridge, UK.
Ljiljana FrukDepartment of Chemical Engineering and Biotechnology, Cambridge University, Cambridge, UK.
Carla P MartinsEarly Oncology TDE, Oncology R&D, AstraZeneca, Cambridge, UK.
Mariano BarbacidSpanish National Cancer Research Centre (CNIO), Madrid, Spain.
Vassilis GorgoulisDepartment of Histology-Embryology, Medical School, National Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-9001-4112
James E KorkolaDepartment of Biomedical Engineering, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Doris M RasslRoyal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.
Gary J DohertyCambridge University Hospitals NHS Foundation Trust, Department of Oncology, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0002-8158-8111
Robert C RintoulCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-3875-3780
Masashi NaritaCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-7764-577X
James D BrentonCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-5738-6683
Daniel Muñoz-EspínEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. dm742@cam.ac.uk.ORCID http://orcid.org/0000-0002-0550-9514

Funding

Cancer Research UK (CRUK) 100005Cancer Research UK (CRUK) A25177Cancer Research UK (CRUK) C62187/A26989Cancer Research UK (CRUK) C62187/A29760Cancer Research UK (CRUK) C63389/A30462Cancer Research UK (CRUK) C9545/A29580EC | European Regional Development Fund (Europski Fond za Regionalni Razvoj) T1EDK02939Evelyn Trust G113971RCUK | Medical Research Council (MRC) MR/R000530/1
6 · The paper itself

Abstract

Platinum-based chemotherapy is commonly used for non-small cell lung cancer (NSCLC) and high-grade serous ovarian cancer (HGSOC) treatments, yet clinical outcomes remain poor. Cellular senescence and its associated secretory phenotype (SASP) can have multiple tumor-promoting activities, but both are largely unexplored in these cancers. In this study, using xenograft, orthotopic and Kras

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCellular SenescenceCisplatinDrug Resistance, NeoplasmLung NeoplasmsOvarian NeoplasmsTransforming Growth Factor betaAnimalsCell Line, TumorFemaleHumansMicePyrazolesQuinolinesReceptor, Transforming Growth Factor-beta Type IAntineoplastic AgentsCisplatinLY-2157299PyrazolesQuinolinesReceptor, Transforming Growth Factor-beta Type ITGFBR1 protein, humanTgfbr1 protein, mouseTransforming Growth Factor beta

Identifiers

PMID41634464
PMCPMC12920146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.